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Background: The ﬁnancial burden of medical insurance on the government of Japan has recently become
severe, which has led to the control of outpatient orthopedic reimbursements for common procedures.
On the other hand, the overall disease burden for total hip or knee arthroplasty, decompression for
cervical myelopathy or lumbar spinal canal stenosis, and new surgical technologies to treat other painful
conditions and the post-surgical care related to these procedures has been reduced.
Methods: Medical insurance systems in Japan are generally inﬂuenced by budget-balancing action.
Consequently, the further development of interventional evaluation methods should be promoted. From
the viewpoint of health economics, the value (meaning) of medical intervention can partly be explained
by its cost-effectiveness. In order for appropriate medical reimbursement levels to be set for orthopedic
surgery, the ﬁnancial status of medical institutions needs to be concurrently reviewed. In particular, the
relationship between the expense structure and medical reimbursement must be discussed to evaluate
its role in community medicine system.
Results: Over the past 10 years, medical expenditures have increased by 9.6% in all ﬁelds, whereas the
monthly medical reimbursements per patient have dropped by an average of 17.5%. Remarkably, surgery-
related costs have increased by 36.5%, while other medical costs have decreased by 19.8%. There are a few
reports of cost-utility analyses which investigate interventions such as total hip arthroplasty for hip
osteoarthritis patients (US$ 4,600e70,500/QALY) and laminectomy for patients with spinal canal ste-
nosis. Interventions may be an inevitable part of relative expense control under the current trend;
however, there has been a slight increase in other parameters in response to changes in medical reim-
bursement evaluations - speciﬁcally, in the total income of medical institutions.
Conclusions: If medical professionals such as orthopedic surgeons contribute to the economic value of
orthopedic surgery, it is crucial to clearly establish interventions among the different performances of
medical reimbursement to motivate the increased allocation of management resources. To further
develop this concept, discussions between stakeholders should involve the value of medicine based on
cost and beneﬁt.
© 2016 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.Contents
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Demand for orthopedics is thus increasingwith changes in values
regarding the social trend, a vital medical strategy for prolonging
healthy life expectancy. Total hip or knee arthroplasty, decompres-
sion for cervical myelopathy or lumbar spinal canal stenosis, and
other surgical interventions for painful orthopedic conditions have
beneﬁtted from new technologies, which have reduced the costs of
these procedures and the associated post-surgical care. As the pop-
ulation ages, the demand for orthopedic surgery is increasing as
patients seek pain relief (the major complaint of most patients) and
improved quality of life. While Japan is the world's leading super-
aged society with more than 30% of the population consisting of
elderly people aged 65 years or older, since themedical costs thereof
are mostly covered through the insurance fees of younger genera-
tions alongwith thenational expenditure, it is leading to theﬁnancial
deterioration of the government [1].
The socioeconomic environment surrounding medical care in
Japan is undergoing major reforms to accommodate a super-aging
society. A study of medical economics is therefore essential for
promoting medical interventions that are appropriate to the re-
quirements of orthopedic surgery. At present, however, no studies
have comprehensively documented the medical economics of or-
thopedic surgery.
This paper closely examines the economic challenges and
countermeasures in orthopedic surgery based on an overview of
the socioeconomic values (health economic meaning) in the ﬁeld.
In particular, the trends in cost-effective reimbursement levels
for physician interventions and various procedures will be dis-
cussed, while previously published case studies on the topic of
medical economics or the ﬁnancial burden on the government
will be introduced.2. The socioeconomic trends surrounding orthopedic domain
2.1. Orthopedics is inﬂuenced by budget-balancing actions
Japanese citizens have traditionally shown a deep appreciation
for the value of universal semi-public healthcare. The service is not
taken for granted, which is evident in their understanding that
patients must pay a portion of their medical expenses to sustain the
system. However, the recent economic exhaustion of the medical
system has placed a renewed ﬁnancial burden on the government.
Recently, discussions on this topic have been sought due to the
tightening of medical budgets in association with the super aging
population, the declining birth rate, and advancements in medical
interventions as economic growth in Japan has slowed or declined.
For example, the growth in gross domestic product (GDP) over
the 10-year period from 1997 to 2006 (during which there were
few sudden changes in the stock market) was 12.1%, whereasnational medical expenditure increased two-fold to 22.6%.
Furthermore, the medical expenses of patients with heart disease
and kidney failure increased by a remarkable 43e48% [2]. Currently,
there is a tendency to allocate resources (number of patients are not
managed though medical reimbursement unit prices are managed)
sparingly, through measures such as budget-balancing (Term 1)
actions, while demands have increased (although national medical
expenses in Japan have shown a tendency to increase every year
due to various factors, by controlling medical expenses that reduce
this imbalance, the unit price is believed to have decreased) [3]. The
value of the medical services that are provided may therefore
deviate from their reimbursement value.
In comparison to all medical procedures, medical expenditure
for diseases of the musculoskeletal system and connective tissue
increased by 9.6% (for both inpatients and outpatients) over the 10-
year period from 1997 to 2006, while the average unit price of
medical reimbursement billing in the ﬁeld dropped 17.5% from 2.0
(thousand points/case/month) to 1.7 (thousand points/case/month;
Table 1). The overall picture suggests that reimbursement for or-
thopedics is also inﬂuenced by budget-balancing actions.2.2. Surgical reimbursement in orthopedic domain
The total medical expenditure (the total reimbursement for
department hospitalization and surgery) orthopedic surgery has
increased by 94% over the past 10 years, and the unit price of
medical reimbursement billing has risen by 36.5% from 27.6
(thousand points/case/month) to 37.2 (thousand points/case/
month; Table 1). This increasing trend is higher than that for the
average unit price (31.4%) for all surgical cases, which suggests that
orthopedic surgery has been treated relatively favorably in past
medical reimbursement reforms.
A closer look at orthopedic surgery indicates that the trends in
medical reimbursement evaluations differ depending based on the
diagnosis and the surgical procedures that are involved. There are
also constraints on the data analyses, which makes organization by
individual procedures (the operation code in Japan is K-code)
difﬁcult; however, if we compare the procedures that have a very
good medical track record, we observe that the unit price of med-
ical reimbursement billings over the past 10 years for arthropathy
and intervertebral disc disorder procedures has increased by
approximately 54e81%, whereas the unit price of inﬂammatory
multifocal joint disorder procedures has decreased by approxi-
mately 30%e12% (Table 2). This suggests that the allocation of re-
sources (medical reimbursement) has changed in the procedures
that are performed in orthopedic surgery.
There are three possible reasons for this variation: 1) new trends
in interventional innovations such as minimally-invasive treat-
ments; 2) the inﬂuence of increases in medical demand and in the
medical insurance budget; and 3) the presence or absence of
Table 1
Trends in medical costs (total medical costs and average monthly billings) by area over the past 10 years.
(Supplement) The overall area comprises the total data for the medical department both in and out-patient of hospital fee (all medical practice). “Surgery” indicates the data
related to hospitalization in the medical department for surgery (surgical actions only).
(Material) Created from the annual Survey of medical care activities in public health insurance (Ministry of Health, Labour and Welfare).
(Source) Takura T. Future direction of heart failure treatment from the perspective of medical policies. Internal medicine. 2014 Mar;113(3):425e30.
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to explain such evidence to the stakeholders. Various factors,
including those listed above, are involved at multiple levels in
medical reimbursement reform.2.3. The cost structure of orthopedics with a low interventional cost
evaluation
Historically, the Japanese medical reimbursement and payment
system has been maintained and managed by the National Health
Insurance Association. At present, the balance of payment with
regard to the semi-public national health insurance is going into
the red. This should therefore be considered in conjunction with
individual medical reimbursement unit prices in discussions on the
clinical economic value of medical interventions in orthopedic
domain (with the deterioration of the balance of payments for
Japanese health insurance due to ﬁnancial issues, the amount paid
for orthopedics has come into question). To evaluate the role of
orthopedic surgeons relative to the medical needs of theTable 2
Trends in the unit price of each surgery in the ﬁeld of orthopedic surgery.
Musculoskeletal system and connective tissue diseases
Total medical costs for the overall area (1000 points/month)
Average monthly billings for the overall area (points/case)
Total medical costs for overall surgery (1000 points/month)
Average monthly billings for overall surgery (points/case)
Surgery for inﬂammatory multifocal joint disorder (points/case)
Surgery for arthropathy (points/case)
Surgery for spinal disorder (points/case)
Surgery for intervertebral disc disorder (points/case)
Surgery for bone density and structure disorders (points/case)
Reference: Average monthly billings for the overall area of surgery (points/case)
(Supplement) The overall area comprises the total data for the medical department both
for hospitalization in the medical department (only surgical actions).
(Data) Created from the annual Survey of Medical Care Activities in Public Health Insura
(Source) Takura T. Arrangement of Public Insurance Fee from Viewpoint of Socioecon
Jun;47(6);575e80.community, there is a particular need to discuss the relationship
between cost structure and reimbursement.
Fig. 1 summarizes the changes in cost structure in orthopedic
domain over the past 10 years [4]. When medical income is deﬁned
as 100, material costsþ depreciation costs have increased from 32%
to 33%, whereas labor costs have relatively decreased from 59% to
46%. In other words, it is inferred that regarding medical manage-
ment reﬂecting the shift in medical service evaluations (medical
income), while investments in “medical supplies” have seen a
tendency to slightly increase, there is conversely a trend towards
controlling investments in “medical skill and art.”
The contribution of medical professionals such as orthopedic
surgeons is responsible for most of the social value of orthopedics
and it is crucial to clearly place interventions among the parameters
of medical reimbursement to promote the increased allocation of
management resources for orthopedic procedures. Since the data
related to this topic are insufﬁcient, more detailed studies are
required to draw the convincing conclusions in discussions on the
salary range or the other working conditions of orthopedic sur-
geons to social mission.1997 2006 Rate of growth (from 100% in 1997)
10,371,673 11,363,338 109.60%
2071 1709 82.50%
369,199 718,626 194.60%
27,261 37,206 136.50%
36,369 25,093 69.00%
41,867 64,726 154.60%
36,058 31,900 88.50%
9,324 16,905 181.30%
29,993 25,883 86.30%
17,906 23,530 131.40%
inside and outside of hospital (all medical actions). Surgery comprises the total data
nce (Ministry of Health, Labour and Welfare).
omicdHow Will Orthpaedic Surgery Become in Future? Clin Orthop Surg. 2012
Fig. 1. Trends in the cost structure of medical management in orthopedic surgery. The interventional costs associated with orthopedic surgery decreasing, whereas the
proportion of material costs is increasing, however, the ratio of an organization attribute was not arranged (management: private hospital and public hospital,
characteristic: scale and region).
Fig. 2. The typical structure of funding for medical reimbursement billing in acute
care. The recipient bears approximately half the cost of insurance in medical care,
whereas public funding, which is broadly borne by the nation, accounts for
approximately one third of the cost.
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domain
3.1. The need for interventional evaluations in orthopedic domain
As with past medical fee revisions, exercising political initia-
tives to make upward revisions is absolutely vital to ensure
further development of the medical system. (The trend in upward
medical reimbursement revisions that has been observed in the
past due to political initiatives is considered to be vital for the
further development of the medical system. However, from the
viewpoint of the sustainable management of the national health
insurance system, medium- and long-term discussions on the
methods of raising the relevant funds should be encouraged. For
example, 48% and 36% of the funding for medical costs related to
the acute care involved in orthopedic treatments, such as surgery,
come from public insurance and public funding (from tax),
respectively. Private funding from the patient (out of pocket
expense) and general private insurance account for 14% and 2%,
respectively (Fig. 2).
Thus the current medical costs of Japan's universal healthcare
system are primarily supported by general tax-payers, who cover
almost 40% of the cost, rather than by clear national health insur-
ance premiums [5]. Approximately 30% (FY 2008) of the general
accounting, which forms the basis of public funding is covered by
government bonds (national debt), which supports the medical
Fig. 3. A method for expressing the value of medical intervention (balance between cost and outcome). If the same cost is applied, the economic value of interventions with higher
value outcomes are desirable.
Table 3
List of the main medical economic evaluation methods for medical interventions.
Analysis
method
Characteristics Disadvantages
Cost-beneﬁt
analysis: CBA
The acquired outcome
(i.e., health improvement)
is also explained in monetary terms.
There has long been reluctance in
clinical settings to convert health to a monetary value.
Cost-effectiveness
analysis: CEA
Uses prolonged life expectancy,
reduction in morbidity and other
factors as indicators.
Uses many disease-speciﬁc indicators,
making comparison between difference diseases
and interventions difﬁcult.
Cost-utility
analysis: CUA
Uses standards such as quality-adjusted
life years (QALYs), which can simultaneously
evaluate both survival time and quality of life.
Sensitivity can be reduced depending on the disease when used to
measure degree of health, which can make it inappropriate for elderly
individuals with a shorter life expectancy.
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the market valuation of government bonds.
As budget constraints on medical insurance funding and other
costs grow, the dynamics between stakeholders have become
increasingly complex. It is necessary to further promote studies ofFig. 4. The concept of indicators to estimate effects from the viewpoint of the patient
(quality-adjusted life years [QALY]). The quality-adjusted life year (QALY) is a
combination of life years gained and patient quality of life (utility value).appropriate medical reimbursement evaluations that coordinate
the clinical, economic and social values (meaning) of the medical
interventions provided by orthopedic surgeons. Physicians need to
discuss the cost-effectiveness of medical procedures with insured
persons and taxpayers.
3.2. The concept of the health economics value of medical
intervention
The most important step for facilitating appropriate discussion
regarding the distribution of medical resources is quantifying the
value of medical services and the sharing of this information among
the stakeholders. This valuation is often accompanied by difﬁculties
due to vague medical care characteristics which lack any deﬁned
boundaries. However, the value of medicine has been highlighted
due to social changes and other factors surrounding medical care,
and there have attempts in various countries to reﬂect this value in
medical policy and other matters.
Value is generally considered to refer to the meaning or signif-
icance of both tangible and intangible parameters. For example,
value in economics and management can be explained as the in-
vestment to return ratio e and is discussed with indicators repre-
senting this ratio. The concept of value can be arranged to ensure
that better outcomes and the utility of a single budget in a given
business or lower costs in achieving a single outcome indicate a
greater value, with the value of a business increasing with an
Fig. 5. The incremental cost-utility ratio is used to compare incremental cost and
incremental utility to systematize the economic efﬁciency of medical interventions.
The incremental cost-utility ratio reﬂects the spread of discussion by medically and
economically measuring the value of medical intervention.
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health economics value of the medical ﬁeld should also be
considered in terms of an investment, with the return ratio rep-
resenting performance.
In the case of medical services, outcomes are presented as the
return from the degree of health, whereas costs are presented as
medical resource input. Various orthopedic interventions are per-
formed to maintain and improve the health of patients with
musculoskeletal system and connective tissue diseases. This can be
represented as health recovery (medical outcome) ÷ consumed
resources (medical costs) ¼ medical performance (health eco-
nomics value [Fig. 3]).
Although it is not possible to discuss all values in a similar
manner, these measures allow for the beneﬁts and burdens pro-
duced by medical care to be quantitatively interpreted and shared;
which may provide a better medical system for all stakeholders [6].
3.3. Examples of outcome-oriented evaluation methods
One of the methods applied to the evaluation of medical sys-
tems and healthcare programs is a cost-utility analysis (CUA),
which evolved from the cost-effectiveness analysis method (CEA,
Table 3; [7]). Many recent research reports have chosen indicators
that can be applied to utility (the desire and satisfaction of re-
cipients; Term 2) to explain the outcomes of medical in-
terventions. Patient-reported outcomes, (PROs) such as fostering a
sense of security (relieving anxiety) in patients and families, are
gaining public interest. One global standard is the quality-
adjusted life year (QALY), which can be used to concurrently
evaluate both survival time (quantitative beneﬁt) and the quality
of life (qualitative beneﬁt [Fig. 4]).
The CUA method, which uses this standard, adopts cost/QALY
as a unit, where a smaller value indicates higher performance.
Furthermore, the incremental cost-utility ratio (ICUR), which is
used to compare incremental cost and incremental utility, utilizes
this principal to evaluate medical interventions (Fig. 5). The ICUR
is expressed as an incremental cost/incremental utility. Better
performance and a higher health economics value are indicatedwhen the utility exceeds the increase in cost of the medical
intervention. Overseas, this ICUR is sometimes used as a measure
of public beneﬁt. This indicates that discussion account for social
sentiment toward the medical care environment (such as medical
resources) and the disease mechanisms (such as rarity and age),
on the basis of the results of studies on citizens' willingness to pay
(WTP; Term 3) for medical care.
For example, a social consensus can be obtained to bear the
medical costs of approximately $50,000 for one QALY. Thus, any
performance that exceeds this cost can be considered a reasonable
public beneﬁt [8]. In one medical economic study of outpatient
maintenance dialysis in Japan, the cost of 1 QALY gain was deter-
mined to be 6.55e7.88 million yen [9,10].
4. The future direction and health economics evaluations of
orthopedics
4.1. Examples of health economics value in orthopedic surgery
Finally, we will introduce several reported cases in which the
CUA method was applied to orthopedic surgery. Due to the wide
time frame in which clinical research was conducted, the various
study designs, and the case groups that were evaluated, we ﬁnd
that many evaluations of medical interventions, which are based on
health economics principles, are being developed for aspects of
orthopedic surgery that range from surgical therapy to pharma-
cotherapy or disease prevention [11‒21].
For example, the CUAs in ﬁve studies on total hip arthroplasty
(THA) showed values of US$ 4600e70,500/QALY, which suggested
that the outcome was generally good (with the exception of the
relapse treatment groups) (Table 4). Other forms of arthroplasty
were also rated relatively well, with respect to the ICUR, according
to the site of intervention [15]. Furthermore, a study that compared
the health economics performance of laminectomy and spinal
fusion in patients with spinal canal stenosis suggested that the
value of laminectomy (US$ 77,600/QALY), was generally good
(Table 5, [16]).
On the other hand, a report which claimed that the medical cost
of vertebral fusion for spinal canal stenosis with spondylolisthesis
was US$ 115,600/QALY, suggests that a further investigation of the
long-term outcomes associated with the procedure is warranted.
Therefore, quantifying the health economics value of medical in-
terventions links clinical issues with social economics by applying
the same objective. Measures for the direction of future research
and development and the efﬁcient use of the relevant interventions
are expected to promote studies from a broader perspective.
QALY does not cover all health conditions or the values of pa-
tients, and some issues and limitations have been pointed out. One
issue arises when a health measurement tools shows weak sensi-
tivity (such as disease state); thus, studies that combine highly
precise methods (such as disease-speciﬁc tools) are preferred.
Moreover, the value of survival may differ in patients with terminal
cancer who have varying levels of life expectancy and patients with
other diseases (such as chronic diseases), suggesting the need for
disease-speciﬁc measures. Health economics evaluations using
QALY and other standards do not necessarily cover all of the dis-
cussions related to clinical settings; thus it is necessary for all
stakeholders to sufﬁciently recognize the need to enhance the
signiﬁcance of these evaluations by expert opinions of clinicians
and other professionals.
4.2. The socioeconomic impacts of disease in orthopedic domain
Pain, including lower back pain, frequently necessitates medical
intervention in orthopedics. Approximately 10e20% of individuals
Table 4
Reported cases of cost-utility analysis (US$/QALY) in total hip arthroplasty.
Author Year No. of
cases
Age Sex
(% of females)
Underlying
disease
BMI Analysis
(observation
period)
Method of
analysis
Purpose Stratiﬁcation Results Unit Reference
number
Lavernia CJ,
et al
2015 175 68 54.10% Osteoarthritis;
68.8%
29.4 4 years CUA(ICUR) － WOMAC;
good group
8256 US$/
Qaly
[15]
(Exacerbation
with age)
－ WOMAC;
poor group
25,937 US$/
Qaly
Rampersaud
YR, et al
2014 99 63 59.60% Osteoarthritis 26.7 5 years ICUR Medical
management
－ 21,702 US$/
Qaly
[14]
Life time ICUR Medical
management
－ 5682 US$/
Qaly
Tso P,
et al
2012 99 63 59.60% Osteoarthritis 26.7 Life time ICUR Medical
management
－ 5321 US$/
Qaly
[13]
R€as€anen P,
et al
2007 120 63.0e69.0 60.00% Osteoarthritis;
61.6%
－ 1 year CUA(ICUR) － Initial
treatment
group
9059 US$/
Qaly
[12]
－ Relapse
treatment
group
70,570 US$/
Qaly
Chang RW,
et al
1996 7e296 85 (Modeling of
multi-edited
report)
Osteoarthritis － Life time CUA(ICUR) － (Comparison
between ACR
class)
4600 US$/
Qaly
[11]
(Supplement) The results of reference 8 are converted into US Dollars using the June 2007 Euro exchange rate.
Table 5
Reported cases of cost-utility analysis (US$/QALY) of other medical interventions in the ﬁeld of orthopedic surgery.
Therapy Morbidity/condition US$/Qaly Reference
Disease-modifying anti-rheumatic drugs(DMARD) Rheumatoid arthritis(primary) 4,849 e 25,355 [17e19]
Prevention(SBST) Lower back pain ICUR: 1,323 (vs. usual care) [20]
Laminectomy Spinal canal stenosis 77,600 [16]
Spinal fusion (with degenerative spondylolisthesis) Spinal canal stenosis 115,600 [16]
Pharmacotherapeutics Fibromyalgia pain symptoms 475,600 [21]
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associated with the exacerbation of health issues [22].
According to a report that examined the socioeconomic effects
of chronic pain [23], chronic pain was to be signiﬁcantly associated
with health and with reduced labor productivity, impaired activ-
ities of daily living, and the increased use of medical and economic
resources. In this study, health was evaluated using the health
measurement tool, SF-12 (Term 4), indirect costs were evaluatedFig. 6. An epidemiological example of the socioeconomic burden of chronic pain. An
analysis of a population of 30,000 individuals, 785 of whom were undergoing treat-
ment, using National Health and Wellness Survey data suggested that socioeconomic
loss occurred in the form of labor productivity losses and other areas due to pain.using theWork Productivity and Activity Impairment (WPAI) (Term
5) questionnaire, and the effects of direct costs (medical costs) were
examined using a regression analysis.
In terms of social economics, long-term sick leave (4.74% vs.
2.74%), working while sick (30.19% vs. 15.19%), overall work
impairment (31.70% vs. 16.82%), indirect costs (Term 6) (1,488,385
vs. 804,634 yen), impaired activities of daily living (33.45% vs.
17.25%), number of visits to the doctor (9.31 vs. 4.08), number ofFig. 7. An overview of a combination index to comprehensively evaluate medical
intervention. Discussion on the evaluation of medical intervention would ideally be
developed with three elements: expert opinions, patient outcomes, and economic
efﬁciency (cost).
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hospitalizations (0.71 vs. 0.34) were some of the results that were
signiﬁcantly high within people with chronic pain (all p < 0.05;
Fig. 6). With regard to the above ﬁndings, it has been reported that
“the economic burden could be reduced by increasing treatment
rates and improving quality of life using a multidisciplinary
approach”.
A similar report argued that chronic pain in sufferers of major
depressive disorder (MDD) is a major factor behind economic loss
[24]. According to this report, the number of hospitalizations and
visits to the emergency department increase as various measures of
a patient's health state decline. A systematic review in Europe
suggested that chronic pain has a large impact on labor produc-
tivity and other factors [25]. On the basis of these cases, orthopedic
diseases can be understood to have a large socioeconomic impact
which should be reduced through appropriate therapeutic
intervention.
4.3. How to medically and economically develop orthopedic
domain
We have provided an overview of the socioeconomic trends
surrounding orthopedics and have described the signiﬁcance and
methods of health economics evaluations as a partial solution to
the problems that have been discussed. We have also introduced
speciﬁc examples of cost-effectiveness and have mentioned points
to consider in relation to the understanding of these approaches
and results. On this basis, the viewpoints necessary to medically
and economically develop orthopedics for the future can be sum-
marized as follows.
To optimize the distribution of medical resources in orthopedic
domain, it is vital to actively promote the evaluation of physician
interventions in discussions of medical reimbursement and other
topics. The difﬁculty (work), cost (resource consumption), and
medical outcome are three speciﬁc methods for evaluating physi-
cian interventions. By performing a combined evaluation that
compensates for the disadvantages and expands the advantages of
these parameters (Fig. 7), we can comprehensively and persua-
sively discuss the medical economic value provided by orthopedic
surgeons [26].
Stretching medical costs without socioeconomic effect or value
inhibits the sustainable development of medical systems and may
prevent the spread of superior medical interventions. Thus, to
further develop themedical systems associated with orthopedics, it
is important to go beyond economic discussions that solely focus on
cost, and to discuss the nature of the national burden (medical
reimbursement) in line with the value (meaning) of a medical
intervention, while discussing this value with stakeholders.
In Japan, due to the decrease in the number of taxpayers as a
result of the decrease in the number of young people, in addition to
the increase in medical insurance expenditures due to the increase
in the number of elderly people, health insurance funding is facing
a deﬁcit in the balance of payments, making it difﬁcult to spend on
newmedical practices in the future. Therefore, in order to maintain
our reputation for medical innovation and a universal healthcare
system, it is important to establish prices taking into consideration
the cost-effectiveness of newer medical technologies.
The discussion of the clinical and economic balance with an eye
to the overall optimization of medical systems should aid in the
further development of this ﬁeld.
5. Conclusion
Going forward, interventional evaluations of services should be
promoted to continue developing this ﬁeld. The health economicsvalue of medical interventions can partly be explained by cost-
effectiveness. According to reports on evaluations that use this
concept, the cost utility of total hip arthroplasty and other surgical
procedures is generally favorable. In contrast, this review suggests
the economic trend of interventions as costs are relatively
controlled and other parameters are slightly increased in response
to changes in medical reimbursement. Thus, the accumulation of
medical economic evidence for physician interventions may be
essential in the development of this ﬁeld. To further develop this
concept, discussions between stakeholders should involve the
value of medicine based on the costs and the beneﬁts.
6. Terminology
Term 1: Budget-balancing
This is also called a balanced budget and refers to the state in
which ﬁnancial expenditure and income are balanced. In the case of
ﬁnancial management based on this principle, actions to reduce
imbalance are taken more aggressively. National medical expen-
diture in Japan tends to increase annually as a result of various
factors, and actions to reduce the imbalance (such as controlling
medical costs) are likely exists in one form or another.
Term 2: Utility value
The utility value is an economic term to explain the level of
desire, satisfaction, and expectation of users in consumption theory
and other concepts. However, it is used as part of health-related
quality of life (HRQOL) in medical care.
Term 3: Willingness to pay
Willingness to pay is a type of stated preference and refers to the
amount that people are willing to pay for themselves or others for
certain things (i.e., health and welfare services).
Term 4: SF-12
The SF-12 is a scientiﬁcally reliable and valid scale used to
measure HRQOL and can be calculated using eight subscales as well
as a summary score.
Term 5: WPAI
TheWork Productivity and Activity Impairment questionnaire is
a self-completed questionnaire and measurement tool that can
evaluate work/study time lost due to illness or a state of reduced
productivity due to illness.
Term 6: Indirect costs
Unlike the costs that are directly incurred to achieve an outcome
(such as a health outcome), indirect costs refer to costs where it is
difﬁcult to draw a link with certain factors or actions (such as a
therapy).
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